J.P. Morgan Raises EPS Estimates in 2012-13 On Amgen Prior to Today's Conference Call

According to a recent report, J.P. Morgan has raised 2012-13 EPS estimates on Amgen AMGN from $5.77/$5.77 to $5.82/$5.87 leading up to a 10 a.m. conference call today to discuss a recent survey J.P. Morgan conducted for the '147 trial. In the survey, J.P. Morgan talked to 25 urologist to better understand the perceptions of '147 trial results. In the report, J.P. Morgan said, "We surveyed 25 community urologists to better understand the perceptions of the ‘147 trial results under the assumption that urologists will become a key prescriber base for Xgeva. Overall, 88% of surveyed urologists viewed a 4.2 mos improvement in bone met free survival as clinically meaningful and 100% of docs viewed the endpoint as 'important'." Amgen closed yesterday at $58.60.